Clinical Trial Update: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) [Phase 1]

View source ↗

Summary

Phase 1 study of ADP-A2M4CD8 as monotherapy or in combination with nivolumab or pembrolizumab in HLA-A2+ patients with MAGE-A4-positive tumors; trial status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Esophageal Cancer
• Esophagogastric Junction Cancer
• Gastric Cancer
• Head and Neck Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• ADP-A2M4CD8
• Pembrolizumab (pembrolizumab)
• nivolumab (nivolumab)

Snippet

Sponsor: USWM CT, LLC | Conditions: Endometrial Cancer, Esophageal Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING